Immunoassays Compared for Diagnosis of Acute Murine Typhus Infections
|
By LabMedica International staff writers Posted on 10 Sep 2019 |

Image: A photomicrograph of an immunofluorescence assay (IFA) for Rickettsia (Photo courtesy of Fuller Laboratories).
Murine typhus is a disease transmitted by fleas and is caused by intracellular gram-negative bacteria called Rickettsia typhi, and manifested clinically with acute fever, chills, muscle pain, nausea, vomiting, stomach pain, cough and rash.
Appropriate rapid diagnostics are needed to distinguish it from other infections, as patient management varies. Due to low rickettsemia during acute illness, the sensitivity of real-time polymerase chain reaction (PCR) is highly variable. Thus, sero-diagnosis using immunofluorescence assay (IFA) remains the gold standard.
Scientists working with the Indonesia Research Partnership on Infectious Disease (Jakarta, Indonesia) obtained samples from eight government referral teaching hospitals in seven provincial capitals. Paired acute and convalescent plasma samples from 40 cases with confirmed R. typhi and 58 controls with another confirmed infection were used to evaluate the performance of commercial IgM and IgG enzyme-linked immunosorbent assay (ELISA) and IFA. The 58 paired plasma specimens that they used for controls were negative for R. typhi and Rickettsia spp., but positive for other pathogens by culture or molecular testing.
The immunofluorescence assay (IFA) was performed using kits from Focus Diagnostics (Cypress, CA, USA). The dilution for study samples was 1:64, and for provided positive controls was 1:32. Acute and convalescent specimens from each subject were performed simultaneously. Acute and convalescent plasma were tested simultaneously using ELISA kits from Fuller Laboratories (Fullerton, CA, USA). Microwells were coated with the outer surface membrane protein rOmp B purified from R. typhi. Optical density (OD) was measured at a wavelength of 450 nm.
The team reported that sensitivity and specificity of combined ELISA IgM and IgG anti-R. typhi using paired specimens were excellent (95.0% and 98.3%, respectively), comparable to combined IFA IgM and IgG (97.5% and 100%, respectively); sensitivity of ELISA IgM from acute specimens only was poor (45.0%), but specificity was excellent (98.3%). IFA IgM was more sensitive (77.5%), but less specific (89.7%) for single specimens. IgM was detected as early as day three of fever by ELISA and day four by IFA. Starting from day nine of illness, IgM was detected in all cases by IFA, while ELISA missed two specimens (days 10 and 25).
The authors concluded that their data supports the validity of ELISA in the diagnosis of R. typhi infection. As the specificity in acute specimens as well as sensitivity and specificity in convalescent specimens and paired specimens were excellent, ELISA is recommended when fluorescence microscopy is not feasible. However, IFA remains the method of choice if resources are available. ELISA is appropriate for resource-limited settings as it is easy to read, is objective, and has a high throughput. The study was published on August 26, 2019, in the journal Vector-Borne and Zoonotic Diseases.
Related Links:
Indonesia Research Partnership on Infectious Disease
Focus Diagnostics
Fuller Laboratories
Appropriate rapid diagnostics are needed to distinguish it from other infections, as patient management varies. Due to low rickettsemia during acute illness, the sensitivity of real-time polymerase chain reaction (PCR) is highly variable. Thus, sero-diagnosis using immunofluorescence assay (IFA) remains the gold standard.
Scientists working with the Indonesia Research Partnership on Infectious Disease (Jakarta, Indonesia) obtained samples from eight government referral teaching hospitals in seven provincial capitals. Paired acute and convalescent plasma samples from 40 cases with confirmed R. typhi and 58 controls with another confirmed infection were used to evaluate the performance of commercial IgM and IgG enzyme-linked immunosorbent assay (ELISA) and IFA. The 58 paired plasma specimens that they used for controls were negative for R. typhi and Rickettsia spp., but positive for other pathogens by culture or molecular testing.
The immunofluorescence assay (IFA) was performed using kits from Focus Diagnostics (Cypress, CA, USA). The dilution for study samples was 1:64, and for provided positive controls was 1:32. Acute and convalescent specimens from each subject were performed simultaneously. Acute and convalescent plasma were tested simultaneously using ELISA kits from Fuller Laboratories (Fullerton, CA, USA). Microwells were coated with the outer surface membrane protein rOmp B purified from R. typhi. Optical density (OD) was measured at a wavelength of 450 nm.
The team reported that sensitivity and specificity of combined ELISA IgM and IgG anti-R. typhi using paired specimens were excellent (95.0% and 98.3%, respectively), comparable to combined IFA IgM and IgG (97.5% and 100%, respectively); sensitivity of ELISA IgM from acute specimens only was poor (45.0%), but specificity was excellent (98.3%). IFA IgM was more sensitive (77.5%), but less specific (89.7%) for single specimens. IgM was detected as early as day three of fever by ELISA and day four by IFA. Starting from day nine of illness, IgM was detected in all cases by IFA, while ELISA missed two specimens (days 10 and 25).
The authors concluded that their data supports the validity of ELISA in the diagnosis of R. typhi infection. As the specificity in acute specimens as well as sensitivity and specificity in convalescent specimens and paired specimens were excellent, ELISA is recommended when fluorescence microscopy is not feasible. However, IFA remains the method of choice if resources are available. ELISA is appropriate for resource-limited settings as it is easy to read, is objective, and has a high throughput. The study was published on August 26, 2019, in the journal Vector-Borne and Zoonotic Diseases.
Related Links:
Indonesia Research Partnership on Infectious Disease
Focus Diagnostics
Fuller Laboratories
Latest Microbiology News
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read moreMicrobiology
view channel
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read more
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more





.jpg)

